PHILADELPHIA, PA--(Marketwire - Jun 26, 2012) - DIA 2012 -- Oracle (NASDAQ: [ ORCL ])

News Facts

• [ Oracle Health Sciences ] today announced the availability of the latest version of [ Oracle Health Sciences Translational Research Center ], a platform that enables secondary use of electronic health records, administrative data and omics data to help accelerate biomarker identification for drug discovery, clinical development and translational research.
• The new release expands Oracle Health Sciences Translational Research Center's patient-centric query capabilities, enabling users to create searches that span phenotype and genotype attributes to quickly identify targeted patient populations. For example, users can now set search parameters for a patient's demographics, cost and treatment timeline, combined with a variety of specific genetic variants in a single search to unlock new insights and advance personalized medicine initiatives.
• With the out-of-the-box flexibility, users can also create gene-centric searches, which enable researchers to retrieve and further analyze all available omics data for particular gene sets of interest within a large data set. 
• This new release integrates best-in-class genomic visualization tools that provide holistic views of multiple omics data modalities to enable systems biology-based approaches essential for understanding disease.
• In addition to Oracle Health Sciences Translational Research Center's existing adapters for loading customer-generated molecular profiling data -- as well as public domain data from sources such as Ensembl, The Cancer Genome Atlas, 1000 Genomes, and Pathway Commons -- the new release extends the omics databank by providing pre-built adapters for RNA sequencing (RNA-seq) and SIFT/Polyphen data sets, further speeding time-to-value for end users.
• Running on [ Oracle Exadata Database Machine ], Oracle Health Sciences Translational Research Center provides the high performance and extreme scalability required to deliver real-time query response against extremely large whole genome data sets.
• Oracle Health Sciences Translational Research Center can be deployed on-premise, in the HIPAA-certified [ Oracle Health Sciences Cloud ], or in a hybrid model that leverages both to provide organizations with maximum flexibility in their deployment options. 

Supporting Quote

• "With the latest version of Oracle Health Sciences Translational Research Center, organizations can effectively search across clinical, administrative and molecular data in a single query, drilling down to individual patient level details to ensure fast, accurate cohort identification. This capability is key to unlocking new insights into the molecular basis of disease that can advance personalized medicine," said Neil de Crescenzo, senior vice president and general manager, Oracle Health Sciences. "And, the cloud-based delivery option gives organizations new flexibility to deploy the solution rapidly and cost-effectively."

Supporting Resources

• [ Oracle in Health Sciences ]
• [ Follow Oracle Health Sciences on Twitter ]
• [ Join the Oracle Health Sciences Community on Facebook ]
• [ Oracle Health Sciences on YouTube ]
• [ Oracle Health Sciences Translational Research Center ]
• [ Press Release: Oracle Unveils Oracle Health Sciences Omics Data Bank as Part of Oracle Health Sciences Translational Research Center ]

About Oracle
Oracle engineers hardware and software to work together in the cloud and in your data center. For more information about Oracle (NASDAQ: [ ORCL ]), visit [ www.oracle.com ].

About Oracle in Industries
Oracle industry solutions leverage the company's best-in-class portfolio of products to address complex business processes relevant to health sciences, helping speed time to market, reduce costs, and gain a competitive edge.

Trademark
Oracle is a registered trademark of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.